The diagnostics company reports solid Q1 trading, with adjusted EBITDA performance holding up well despite headwinds. The business is on track to deliver growth for the full year in-line with market expectations.
The healthcare diagnostics company has completed its share buyback programme, repurchasing over 4.6 million shares.
The healthcare diagnostics company has announced a share buyback program.
The healthcare diagnostics company has purchased 200,000 of its own shares at an average price of 21 pence per share.
The healthcare diagnostics company has published its annual report and notice of upcoming AGM.
The healthcare diagnostics company has purchased over 570,000 of its own shares as part of an ongoing buyback program.
The healthcare diagnostics company's directors have purchased additional shares in the business.
The healthcare diagnostics company has appointed a new Chief Executive Officer to lead the business.
The global diagnostics company will announce its full year results and hold investor presentations on March 25, 2025.